Engineered Exosomes Deliver miR-370 Inhibitor to Regulate DNAJB1 and Synergize With miR-25 in Improving SCA3 Mice...

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Spinocerebellar ataxia type 3 (SCA3) is a common inherited ataxia with no effective treatments.
• Current therapies targeting ataxin-3 (ATXN3) mRNA risk depleting essential wild-type ATXN3.
• Novel neuron-targeted, noninvasive delivery strategies are crucial for SCA3 therapeutics.

Purpose of the Study:

• To engineer rabies virus glycoprotein (RVG)-modified exosomes for brain delivery of miR-370 inhibitors in SCA3 mice.
• To investigate the therapeutic potential of upregulating DNAJB1 via miR-370 inhibition for mutant ATXN3 clearance.
• To evaluate the synergistic effects of combining miR-370 inhibitors with ATXN3 mRNA-targeting miRNAs.

Main Methods:

• Systemic administration of RVG-exosomes loaded with miR-370 inhibitors into SCA3 mouse models.
• Assessing changes in DNAJB1 expression, mutant ATXN3 aggregation, and neuronal survival.
• Evaluating motor coordination recovery and neuroprotection in treated mice.
• Investigating combination therapy with miR-25 (targeting ATXN3 mRNA).

Main Results:

• RVG-exosome delivery successfully increased brain DNAJB1 expression in SCA3 mice.
• This led to reduced mutant ATXN3 aggregation, enhanced neuronal survival, and improved motor function.
• Combination therapy with miR-370 inhibitors and miR-25 showed synergistic neuroprotection and ATXN3 reduction.

Conclusions:

• RVG-exosome-mediated miR-370 inhibition is a promising noninvasive strategy for SCA3 by enhancing proteostasis.
• This approach offers neuroprotection and motor function recovery in SCA3 mouse models.
• Combination therapy presents a potent therapeutic paradigm for SCA3 and related neurodegenerative diseases.